Price$1.51+0.02 (+1.34%)
06:15 PM07:30 PM
News · 26 weeks23-50%
2025-10-262026-04-19
Mix690d
- Other5(83%)
- SEC Filings1(17%)
Latest news
25 items- PRBioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingCARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026. The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo1, C Ahlem1, C.L. Reading1, S. O'Quinn2, J. Zhan
- SECSEC Form SCHEDULE 13D filed by BioVie Inc.SCHEDULE 13D - BIOVIE INC. (0001580149) (Subject)
- PRBioVie Announces Abstract Accepted for Presentation at AD/PD 2026CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming AD/PD 2026 Advances in Science & Therapy annual meeting, to be held March 17-21, 2026 in Copenhagen, Denmark. The abstract, titled Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson's Disease (SUNRISE-PD) (J. Palumbo1, C Ahlem1, C.L. Rea
- PRJoin Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on March 4, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss BioVie's investigational drug candidate bezisterim (NE3107), a first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cogniti
- PRBioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual MeetingCARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer's Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL. The two abstracts have been accepted for presentation as posters during a session to be held on February 18, 2026. Details of the abstracts are as follows: Abstract Title: Bezisterim-Associated Anti-i
- SECSEC Form 10-Q filed by BioVie Inc.10-Q - BIOVIE INC. (0001580149) (Filer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Palumbo Joseph M4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Kim Joanne Wendy4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Rogich Sigmund4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Do Cuong V4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Sherman Michael Edward4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Farag Kameel D.4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Chappell Amy Suzon4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 4 filed by Director Lang James Paul4 - BIOVIE INC. (0001580149) (Issuer)
- PRBioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim (NE3107) on motor and non-motor symptoms in individuals with early-stage Parkinson's disease (PD) who have not been treated with
- SECSEC Form S-8 filed by BioVie Inc.S-8 - BIOVIE INC. (0001580149) (Filer)
- PRJoin Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie's first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduce
- SECSEC Form EFFECT filed by BioVie Inc.EFFECT - BIOVIE INC. (0001580149) (Filer)
- SECBioVie Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BIOVIE INC. (0001580149) (Filer)
- SECBioVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BIOVIE INC. (0001580149) (Filer)
- SECSEC Form 10-Q filed by BioVie Inc.10-Q - BIOVIE INC. (0001580149) (Filer)
- INSIDERSEC Form 3 filed by new insider Farag Kameel D.3 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chappell Amy Suzon3 - BIOVIE INC. (0001580149) (Issuer)
- PRBioVie to Host Live Investor Webinar and Q&A on Oct. 8CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company's first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer's, Parkinson's, and long COVID. Clinical studies have shown encouraging signals of improved cognition, motor function and
- SECSEC Form DEF 14A filed by BioVie Inc.DEF 14A - BIOVIE INC. (0001580149) (Filer)